Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

NCT01757197 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Glucocorticosteroid Refractory Acute GVHD

Interventions

DRUG: Toclizumab

Sponsor

Weill Medical College of Cornell University